Ravulizumab and COVID-19

Summary

Ravulizumab and COVID-19 is a clinical trial^[1].

Key Facts

• Ravulizumab and COVID-19 is in the country of United States^[2].
• Ravulizumab and COVID-19's instance of is recorded as clinical trial^[3].
• Ravulizumab and COVID-19's start time is recorded as +2020-12-18T00:00:00Z^[4].
• Ravulizumab and COVID-19's end time is recorded as +2023-05-31T00:00:00Z^[5].
• Ravulizumab and COVID-19's main subject is recorded as COVID-19^[6].
• Ravulizumab and COVID-19's main subject is recorded as thrombocytopenia^[7].
• Ravulizumab and COVID-19's main subject is recorded as pneumonia^[8].
• Ravulizumab and COVID-19's number of participants is recorded as {'unit': '1', 'amount': '+32'}^[9].
• Ravulizumab and COVID-19's title is recorded as C5 Complement Inhbition Using Ravulizumab for the Treatment of COVID-19 Induced Thrombotic Microangiopathy^[10].
• Ravulizumab and COVID-19's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[11].
• Ravulizumab and COVID-19's ClinicalTrials.gov ID is recorded as NCT04570397^[12].
• Ravulizumab and COVID-19's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+85'}^[13].
• Ravulizumab and COVID-19's research intervention is recorded as ravulizumab^[14].
• Ravulizumab and COVID-19's research intervention is recorded as complement inactivating agents^[15].
• Ravulizumab and COVID-19's research intervention is recorded as immunosuppressive drug^[16].
• Ravulizumab and COVID-19's research intervention is recorded as immunologic factor^[17].
• Ravulizumab and COVID-19's clinical trial phase is recorded as phase III clinical trial^[18].
• Ravulizumab and COVID-19's research site is recorded as Brigham and Women's Hospital^[19].
• Ravulizumab and COVID-19's research subject recruitment status is recorded as recruiting^[20].
• Ravulizumab and COVID-19's study type is recorded as interventional study^[21].